How do you handle Grade 3-4 standard infusion reactions with Amivantamab?

Fortunately, G3+ infusion reactions with amivantamab are uncommon. In the CHYSALIS phase I study which led to approval for EGFR exon 20 (Park et al., PMID 34339292), G3+ infusion reactions were only seen in 3% of patients. But grade 1-2 infusion reactions were fairly common.

Infusion reactions tend t...